Mumbai: After successful delivery of ‘Covishield’, Serum Institute of India (SII) CEO Adar Poonawalla is hoping to launch another Covid-19 vaccine in the upcoming months. The new vaccine named ‘Covovax’ is being created by Novavax. The SII has applied to the Drugs Controller General of India (DCGI) and the application is currently under survey. Poonawalla has claimed that there are amazing results of Covovax vaccine.
The application would be evaluated completely by the expert panel after the firm submits a re-examined application, added the official. The Pune-based firm has now created Covishield vaccine, co-developed by the University of Oxford and British-Swedish company AstraZeneca. The Centre has purchased 11 million doses of Covishield vaccine for the progressing vaccine drive.
Taking to his official Twitter handle, Adar Poonawalla said, “Our partnership for a COVID-19 vaccine with Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch COVOVAX by June 2021.” Earlier, a government official had confirmed that the Serum Institute has applied to the DCGI for its Novavax vaccine. The Subject Expert Committee (SEC) sometime back has reviewed their application and asked them to submit the revised protocol.
The country launched its Covid-19 vaccination drive from January 16 in what Prime Minister Narendra Modi has called the world’s biggest inoculation program with priority to be given to about three crore healthcare and essential workers.